White Lauren Insider Trades

Insider Trading History

Track insider trading activity for White Lauren. See latest buy and sell transactions across all companies.

Holdings

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price

Insider Trades History

Company
Holding Value
Last Transaction
Sale/Purchase
Amount
Price
Current Price
Immunogen
Immunogen IMGN
Svp, CFO AND PFO
Holding Value $0 0 shares
Last Trade
Feb 12, 2024 Purchase (Sale to Issuer)Shares sold back to the company, such as a repurchase or tender.
$9.85M 315,494 shares
$31.24
$31.24
Immunogen
Immunogen IMGN
Svp, CFO AND PFO
Holding Value $610k 19,519 shares
Last Trade
Feb 01, 2024 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$573k 19,519 shares
$29.36
$31.24
Immunogen
Immunogen IMGN
Svp, CFO AND PFO
Holding Value $9.24M 295,975 shares
Last Trade
Sep 18, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$4.65M 295,975 shares
$15.71
$31.24
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $69.6k 16,500 shares
Last Trade
Aug 30, 2023 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$6.59k 2,250 shares
$2.93
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $138k 32,686 shares
Last Trade
Aug 30, 2023 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$1.94k 661 shares
$2.93
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $141k 33,347 shares
Last Trade
Aug 30, 2023 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$6.59k 2,250 shares
$2.93
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $528k 125,000 shares
Last Trade
Feb 13, 2023 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$709k 125,000 shares
$5.67
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $21.5k 5,097 shares
Last Trade
Jan 30, 2023 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$10.1k 1,301 shares
$7.78
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $27k 6,398 shares
Last Trade
Jan 30, 2023 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$29.2k 3,750 shares
$7.78
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $79.1k 18,750 shares
Last Trade
Jan 30, 2023 Sale (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$29.2k 3,750 shares
$7.78
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $11.2k 2,648 shares
Last Trade
May 26, 2022 Sale (In-Kind)Shares used to pay exercise costs or tax withholding, or another in-kind transfer tied to compensation.
$7.73k 1,102 shares
$7.01
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $15.8k 3,750 shares
Last Trade
May 25, 2022 Purchase (Option Exercise)Shares acquired or sold by exercising stock options or converting another derivative security.
$25.5k 3,750 shares
$6.81
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $422k 100,000 shares
Last Trade
Feb 14, 2022 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$2.27M 100,000 shares
$22.71
$4.22
C4 Therapeutics
C4 Therapeutics CCCC
Chief Financial Officer
Holding Value $574k 136,000 shares
Last Trade
Jun 21, 2021 Purchase (Award)Shares received as a grant, bonus, or other company award rather than an open-market purchase.
$5.23M 136,000 shares
$38.49
$4.22

See more insider trades for free

Join Stockcircle to see more insider trades and be the first to know about new executive transactions.

Sign Up